Towards guidelines for informed consent for prospective stem cell research by Greenberg, J et al.
46     August 2015, Vol. 8, No. 2, Supplement 1    SAJBL
Stem cells have been classified broadly into three 
categories: 
• Adult stem cells
• Multipotent mesenchymal stem cells  
• Pluripotent stem cells, including embryonic stem (ES) cells and 
induced pluripotent stem cells (iPSCs).
Skin epidermal cells (keratinocytes) are a typical example of adult 
stem cells; they can be harvested from donor skin samples, cultured 
in vitro and used for research or for treatment, such as for burns. 
These unipotent adult cells can only be grown into skin cells and 
are covered in current consent protocols. In contrast, mesenchymal 
stem cells can be obtained from a variety of tissues, including bone 
marrow, umbilical cord, fetal and adipose tissues. Bone marrow cells 
have been used for treating haematological conditions for over 70 
years. The transplanted cells home into and populate the recipient’s 
bone marrow and when successful, differentiate into all the blood 
cell types. Many studies have shown these cells to differentiate 
into several different cells types in culture, including adipocytes, 
chondrocytes and osteoblasts.[1] Mesenchyme stem cells also seem to 
have the ability to modulate inflammatory reactions, and are being 
used in treatment trials for pathologies resulting from, for example, 
lung injury, myocardial infarction, diabetes, sepsis and stroke.[2]
Pluripotent stem cells are capable, at least in vitro, of differentiating 
into all the types of cells in the body. However, the ability of 
pluripotent cells to become a part of a fully functional normal 
tissue remains to be proven, though many animal studies and some 
human studies provide exciting prospects.[3] Human embryonic stem 
(hES) cells obtained from the inner cell mass of the blastocyst can 
be considered as the ‘gold standard’ of pluripotency, but because 
embryos must be destroyed to obtain these cells, the harvesting 
and use of hES cells is limited by their availability and is constrained 
and regulated by complex ethical and moral issues.[4] The stem cell 
community was therefore greatly excited when, in 2006, Takahashi 
and Yamanaka showed that it was possible to ‘reprogramme’ fully 
mature differentiated cells back into pluripotency by the addition 
of genes that reactivate the embryonic genetic programme.[5,6] 
We, and many groups around the world, immediately saw the 
potential of these cells to study development and have established 
‘disease-in-the-dish’ models to help elucidate the cellular aetiology of 
diseases and for patient-specific drug-testing studies.[7] With the rapid 
exploration of iPSC technology and the burgeoning research output, 
it is not surprising that the first trial of iPSC for the treatment of age-
related macular degeneration is underway.[8] However, the rise of iPSC 
technology has brought into focus many new ethical questions that 
must be addressed and resolved.  
Ethics
Medical research involving human subjects or human biological 
material should be designed to promote the best interests of the 
study participants. Disclosure of research protocols which affect 
the participant directly and in some instances, indirectly, is non-
negotiable and should be communicated to participants in such 
a manner that they have no uncertainties about their rights in the 
study. The methods of conveying this information to participants are 
open to much debate and the World Medical Association (WMA) has 
developed the declaration of Helsinki (DoH) as a statement of ethical 
principles which should govern medical research on human subjects 
and identifiable human biological material.[9] Although primarily 
addressing physicians, the DoH policy is widely used by scientific 
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researchers and underpins the informed 
consent (IC) requirement for ethical approval 
by Human Research Ethics Committees 
(HRECs) at academic institutions. 
In South Africa (SA), we propose that 
IC guidelines for stem cell research should 
attempt to cover all the aspects in the DoH. 
This should take into account the local 
challenges resulting from the diversity 
of culture, religion and socioeconomic 
status of the subjects in SA and in Africa. 
However, regardless of how carefully the 
IC is worded, the implementation of the 
recommendations of the DoH relies on the 
researchers’ truthfulness, humanity, respect 
for others and sensitivity to social and 
cultural issues. Without a continuous audit 
of the study progress and of the researchers’ 
adherence to the IC commitment, ethical 
deviations may escalate. 
Consent guidelines
Whether or not one agrees that individual 
consent is warranted for any cell type 
derived from a patient’s sample, a more 
fundamental issue revolves around the 
patient’s competency in making the 
decision to allow for the use of their 
biological material. Stem cells pose 
challenges that the standardised IC 
documents for collection of blood and DNA 
often do not address. A case in point is the 
generation of iPSCs with their potential 
to become any cell type in the body and 
therefore the long-term potential use 
for these cells in clinical translational 
studies in the future.[5,6] It is almost im-
possible to provide accurate information 
about the path that iPSCs will traverse in 
their lifetime, given the rapid advances 
in this field.[10] However, when conveying 
information to study participants, efforts 
should be made to be explicit regarding 
current controversial issues in this regard. 
For example, it should be stated that germ 
line cell derivatives and reproductive 
applications will not be attempted or 
developed with the generated iPSCs, 
and one should provide the reassurance 
that current legislation prohibits certain 
uses of biological samples, such as the 
reproductive cloning of humans (National 
Health Act 61/2003: 57(1)). In SA, with its 
social challenges and significant rate of 
illiteracy, how does one convey information 
to a layperson about the reprogramming of 
somatic cells back to their embryonic state? 
We believe that the emphasis must be on 
ensuring that the relevant information is 
imparted in a clear and simple manner and 
in the appropriate language. Innovative 
ways of communication may be required. 
Moreover, it is noteworthy that in Japan, 
the Japanese Minister of Health, Labour 
and Welfare has initiated a ‘new five-year 
clinical trial activation plan’ running role-
play workshops on IC to boost public 
understanding of clinical trials with stem 
cells (see Kusenose et al. in this edition).
 The University of Cape Town (UCT), 
Human Research Ethics Committee (HREC) 
has the following recommendations for 
IC during the collection and storage of 
biological material from human subjects 
and recommends the use of videotapes, 
photographs or diagrams of research 
procedures, pre-visits to the research site 
to see equipment, group discussions, web 
sites and comics that explain the nature of 
the research where applicable; as well as 
brochures and guidance on participants’ 
rights in research (see the UCT FHS 
HREC website re human ethics standard 
operating procedures). 
As stem cell research is so complex, it 
may be difficult for patients to comprehend 
what exactly scientists are attempting to 
Table 1. Issues to address when compiling informed consent forms for stem cell 
related research (based on recommendations by Lowenthal et al.[13] 2012)
Point Details
Purpose of the study Give a description of the study. This may be detailed if the samples 





stem cells/adult stem 
cells?
Provide a simple explanation of the type of cell that will be obtained, 
and a description of the potential uses of the cell type (for example, 
disease modelling and drug testing).
Details of participation Describe what type of donation will be required (skin biopsy, blood 
sample, hair sample, cord blood).
Collection of medical/
clinical information
Outline what medical information will be requested from the 
individual, such as age, sex, family history of disease.
Number and frequency 
of visits required
State whether a single sample will be donated in one visit, or if 
multiple samples will be collected over a period.
Re-contact State whether the participant may be re-contacted in the future 
to obtain additional consent for future projects, to update the 
participant on the progress of the research, or to obtain additional 
health-related information.
Limitations on use of 
cells
Describe the limitations of the use of the donated cells. It may be 
useful to state that all research will comply with applicable federal 
and institutional laws and policies.
Risks Outline any risks associated with the applicable medical procedure 
(skin biopsy or blood donation, etc).
Confidentiality Describe the plans and policies in place to protect the confidentiality 
of the donor, such as password-protected databases, coding, and 
restricted access to lab areas.
Benefits Will there be direct benefit to the donor or their family, or simply to 
the scientific community?
Options State that participation is voluntary.
Amendments to 
consent
Describe what options the donors have if they change their mind. Can the 
sample be withdrawn? Can the material be de-linked from the donor?
Payment State whether the participant will be compensated for their 
participation. You may wish to include a clause about financial 
compensation regarding any future commercial products.
Problems or questions Provide the details of a person and/or group whom the donor may 
contact if they have any further questions or concerns.
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do with a developing technology, which is still often in the 
unknown. Therefore, there is now an urgent need for professionally 
trained staff in SA, who are able to objectively explain the risks and 
benefits of stem cell research to study participants and highlight 
the value of their possible future participation in clinical trials. 
These trained experts could be described as stem cell counsellors 
who could help potential participants navigate through trials; 
explain risks, benefits, and therapeutic alternatives; and provide 
information about unproven transplants offered outside the 
bounds of good clinical practice and ethical research. They would 
also need to work closely with patients enrolled in clinical trials 
and serve as a public resource for patient education, advocacy and 
outreach efforts.[11]
The reason is that despite the dramatic development of gene- and 
stem cell-based therapies in ophthalmology, for example, there 
are still major concerns that need to be addressed concerning the 
promise and pitfalls of communicating these facts to patients as the 
clinical research progresses. At present they could, at best, represent 
a treatment but not a cure and are, as yet, certainly not ‘risk-free’.[12] 
The generation of iPSCs has great potential for future research 
and the scope and extent of their use is limitless. However, it is 
impossible to anticipate the full range of their future application. 
Therefore, regarding prospective collection of biological material 
for future research of this nature, we propose that the consent 
form should be used prudently to assure participants of the ethical 
use and governance of their specimens in SA, as was proposed by 
Lowenthal et al.[13] Some guidelines should be formulated for an 
ethical approach to obtaining comprehensive IC for the collection 
of biological material for the generation of iPSCs for prospective 
research purposes. Broadly, the recommended issues to be addressed 
in IC forms, incorporating requirements for stem cell research, are 
given in Table 1.  
The approach to obtaining IC for stem cell research may be 
considered as a spectrum. On the one end, consent may be 
obtained for a broad, open-ended study, which requires a single 
interaction with the research participant. While this type of consent 
may be facilitative for future research purposes, it can be questioned 
whether this truly embodies ‘informed’ consent, since the full extent 
of future stem cell research potential cannot be predicted. The 
narrow approach to IC can be considered to lie on the other end 
of the spectrum, where participants give consent for their material 
to be used for a very specific purpose. Lowenthal et al[13] suggest 
that an IC ‘middle ground’ can be reached, which allows for broad 
aims, but with clear boundaries with regard to future research. 
This approach relies on a constant dialogue with participants, and 
re-consenting may be required in some cases. Institutions may 
also consider a tiered approach to consent, which uses an opt-in 
or -out system that allows participants to tailor their consent, but 
would require added oversight and monitoring regarding the use 
of individual cell lines. There is the also the question of unlimited 
use of de-identified samples for research purposes that needs 
to be considered.[14] The issue of privacy and confidentiality is a 
major area of concern to potential research participants, given 
that true de-identification of biological material and/or data is 
not always possible, since a small number of genetic variants can 
uniquely identify the donor. The protection and respect of research 
participants’ privacy is of paramount importance.[14]
In 2009 Aalto-Setälä and colleagues discussed that the development 
of iPSCs had reshaped and revolutionised the scientific and political 
arenas of stem cell research.[15] They proposed that iPSCs had provided 
many novel scientific opportunities to study the pathophysiology 
of diseases that had hitherto been impossible. iPSCs have enabled 
scientists to understand more about stem cell biology, identify new 
therapeutic targets and facilitated the testing of novel therapies in vitro. 
Therefore a wait-and-see approach to the therapeutic use of iPSCs is 
proposed. In SA the focus should fall on the use of iPSCs as disease-in-
a-dish models, and that for now we must determine their efficacy and 
safety by using them as pre-clinical cellular models. This time should be 
used constructively and productively to possibly develop prospective 
policies for the use of iPSCs for therapeutic transplantation in the future 
and also to address the scientific, legal and ethical implications of 
establishing and using iPSCs in the laboratory.[10]  
For SA to continue to develop the capacity to incorporate new 
biomedical technologies, it must become proactive in formulating 
clear guidelines for the oversight of IC for future anticipated and as yet, 
unanticipated use of multipotent and pluripotent stem cells in research.
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